Earnings Per Share of $0.26, surpassing estimates and indicating strong profitability.
Revenue exceeded expectations at approximately $5.71 billion, showcasing efficient management.
Financial Ratios such as P/E, price-to-sales, and debt-to-equity highlight investor confidence and financial health.

SMMNY, traded on the PNK exchange, is a prominent player in the medical technology sector. On February 6, 2025, the company reported earnings per share of $0.26, surpassing the estimated $0.25. This indicates strong profitability and efficient management. The company’s revenue also exceeded expectations, reaching approximately $5.71 billion compared to the estimated $5.57 billion.
The company’s financial metrics provide further insight into its performance. With a price-to-earnings (P/E) ratio of approximately 16.43, investors are willing to pay $16.43 for every dollar of earnings, reflecting confidence in SMMNY’s future growth. The price-to-sales ratio of about 2.85 suggests that the market values the company at 2.85 times its sales, indicating a healthy market perception.
SMMNY’s enterprise value to sales ratio is around 3.46, which shows the company’s total valuation compared to its sales. This metric is crucial for understanding how the market values the company’s overall operations. Additionally, the enterprise value to operating cash flow ratio of approximately 28.27 highlights the company’s valuation in relation to its cash flow from operations, a key indicator of financial health.
The earnings yield of about 6.08% represents the return on investment for shareholders, suggesting a solid return relative to the company’s earnings. The debt-to-equity ratio of approximately 0.89 indicates a balanced approach to financing, with a reasonable proportion of debt used to finance assets. Lastly, the current ratio of around 1.25 suggests that SMMNY is well-positioned to cover its short-term liabilities with its short-term assets, ensuring financial stability.